Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2009 | 1 |
2010 | 1 |
2013 | 1 |
2019 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
Identifying practice gaps to optimize medical care for patients with nonalcoholic fatty liver disease.
Dig Dis Sci. 2013 Oct;58(10):2809-16. doi: 10.1007/s10620-013-2740-8. Epub 2013 Jul 11.
Dig Dis Sci. 2013.
PMID: 23843097
A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma-Initial, Maximum, Last Classification.
Vutien P, Dodge J, Bambha KM, Nordstrom EM, Gralla J, Campbell K, Levek C, Nydam T, Fix O, Ioannou G, Biggins SW.
Vutien P, et al.
Liver Transpl. 2019 Apr;25(4):559-570. doi: 10.1002/lt.25422.
Liver Transpl. 2019.
PMID: 30706653
For each patient, HCC burden was measured at 3 points on the waiting list: initial (I), maximum (M) total tumor diameter, and last (L) exception petition. HCC burden at these 3 points were classified as (A) B) Milan, (C) >Milan to University of California, S …
For each patient, HCC burden was measured at 3 points on the waiting list: initial (I), maximum (M) total tumor diameter, and last (L) excep …
Item in Clipboard
Treatment of nonalcoholic fatty liver disease in children: TONIC trial design.
Lavine JE, Schwimmer JB, Molleston JP, Scheimann AO, Murray KF, Abrams SH, Rosenthal P, Sanyal AJ, Robuck PR, Brunt EM, Unalp A, Tonascia J; Nonalcoholic Steatohepatitis Clinical Research Network Research Group.
Lavine JE, et al.
Contemp Clin Trials. 2010 Jan;31(1):62-70. doi: 10.1016/j.cct.2009.09.001. Epub 2009 Sep 15.
Contemp Clin Trials. 2010.
PMID: 19761871
Free PMC article.
Clinical Trial.
Participants were randomized to receive either metformin (500 mg b.i.d.), vitamin E (400 IU b.i.d.), or placebo for 96 weeks. This protocol was approved by all participating center Institutional Review Boards (IRBs) and an independent Data and Safety Monitoring Boar …
Participants were randomized to receive either metformin (500 mg b.i.d.), vitamin E (400 IU b.i.d.), or placebo for 96 weeks. …
Item in Clipboard
Cite
Cite